Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Otsuka's US Subsidiary CEO to Become New President, Taiho Pharmaceutical
December 13, 2011
- Wholesalers Eager to Begin Category-Based Price Negotiations After FY2012 Price Revision
December 13, 2011
- Ohara Pharmaceutical to Initiate Clinical Trials for Leukemia Treatment Drug Requested for Development
December 13, 2011
- OncoTherapy’s Subsidiary Immunas Receives Milestone Payment from Kyowa Hakko Kirin
December 13, 2011
- EC Grants Marketing Authorization for Takeda’s ARB Edarbi
December 12, 2011
- Fuso Withdraws NDA for PHN Treatment in Japan, Prepares for Additional Studies
December 12, 2011
- Will Ilaris Remain an “Ultra-orphan” Drug?
December 10, 2011
- DODA Survey Shows MR’s Average Annual Income at ¥6.61 Million, 6th Highest by Occupation
December 9, 2011
- GSK’s Ofatumumab and Pazopanib Granted Orphan Drug Designation
December 9, 2011
- Kyowa Kirin Aims to Make RNAi Drugs Future Pillar: Dr Shitara
December 9, 2011
- Kobayashi, President of Mitsubishi Chemical HD Expects Continuous Growth of Pharmaceutical Business
December 9, 2011
- Takeda Says FDA Committee Indicates Recommendation for Peginesatide
December 9, 2011
- Shionogi Announces Favorable Decision in Fortamet Preliminary Injunction Proceedings
December 9, 2011
- MTPC Sets Up External Committee to Promote Appropriate Use of Telavic
December 8, 2011
- Mebiopharm, Nawaloka HD to Establish Joint Venture in Sri Lanka
December 8, 2011
- Towa Pharmaceutical to Expand Dealings with Regional Foundation Hospitals
December 7, 2011
- Growth for All Products Is Indispensable: President Alvarez of MSD
December 7, 2011
- FDA Accepts NDA for US BMS/US Pfizer’s Apixaban
December 7, 2011
- US Merck to Establish Asia R&D Headquarters in Beijing
December 7, 2011
- Sandoz Aiming for Top-10 Position in Japan within 3-5 Years
December 7, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…